Workshop Series

Workshop Series


Medlior is offering a workshop series to inform hot topics in HEOR to our clients and collaborators.

Are you planning to launch an innovative therapy for a rare disease within the next two years?

Medlior and MORSE Consulting are pleased to offer a workshop dedicated to the reimbursement considerations for drugs for rare disease indications.

The workshop will be tailored for market access teams working on rare disease assets to understand the fundamentals of outcomes-based agreements (OBAs) and steps in generating real-world evidence (RWE) to support these agreements.

The specific topics for the workshop include:

  • Navigating the Landscape: Understanding possibilities for OBAs in rare diseases and characteristics of a product and therapeutic area best suited for successful OBAs in Canada
  • Data-Driven Success: How to assess your RWE needs for HTA and negotiations
  • Canadian Requirements: Identifying Canadian RWE sources, processes, and requirements for accessing and generating necessary data
  • Strategic Planning: Building an RWE strategy that serves multiple purposes across market access
  • Leveraging Patient Support Programs: Effective strategies for partnership and success

The 2-hour workshops will be held virtually and led by senior staff from MORSE and Medlior. All participants will receive a comprehensive PDF of the workshop content, as well as Q&A notes that could serve as a future reference.

Contact us at for more information on pricing and availability.

  • Tara Cowling, President and Managing Principal, Medlior
  • Suzanne McMullen, Senior Principal, Medlior
  • Sang Mi Lee, Director of Innovative Access Solutions, MORSE Consulting
  • Jaclyn Beca, Director of Pharmacoeconomics and RWE, MORSE Consulting

Are you planning to launch an innovative therapy in oncology within the next two years?

Medlior and MORSE Consulting are pleased to offer a workshop dedicated to the reimbursement considerations for drugs for oncology indications.

The workshop will be tailored for market access teams working on oncology assets to understand the best practices for generating and/or leveraging real-world evidence (RWE) to support payer negotiations and potential outcomes-based agreements (OBAs) in Canada.

The specific topics for the workshop include:

  • Navigating the Landscape: Understanding possibilities for OBAs for oncology drugs, including Project Orbis and drugs without OS data, and characteristics of a product and indication best suited for successful OBAs in Canada
  • Data-Driven Success: How to assess your RWE needs for HTA and negotiations
  • Canadian Requirements: Identifying Canadian RWE sources, processes, and requirements for accessing and generating necessary data
  • Strategic Planning: Building an RWE strategy that serves multiple purposes across market access
  • Leveraging Patient Support Programs: Effective strategies for partnership and success

The 2-hour workshops will be held virtually and led by senior staff from MORSE and Medlior. All participants will receive a comprehensive PDF of the workshop content, as well as Q&A notes that could serve as a future reference.

Contact us at for more information on pricing and availability.

  • Tara Cowling, President and Managing Principal, Medlior
  • Suzanne McMullen, Senior Principal, Medlior
  • Sang Mi Lee, Director of Innovative Access Solutions, MORSE Consulting
  • Jaclyn Beca, Director of Pharmacoeconomics and RWE, MORSE Consulting

1.Introduction to RWD/RWE
2.Overview of Canadian RWD sources
Pros and cons for industry-sponsored studies
3.Process and requirements for accessing data
4.Latest trends
Outcomes-based agreements
CADTH and INESSS guidance
Global applications
5.Case study examples

The workshop is 2 hours and led by Tara Cowling, Founder and President of Medlior, and Eileen Shaw, Principal of RWE at Medlior. The workshop will be hosted by Medlior on the Zoom platform. Organizational attendance is limited to 100 attendees. The cost for the workshop is $6400 CAD. After the meeting, a PDF copy of the presentation slide deck along with Q&A meeting notes will be provided.

1.Overview of CADTH procedures for manufacturer clinical evidence
Former –vs– New changes (October 2022)
2.Introduction to the GRADE tool
3.Live demonstration of the GRADE tool
4.International use of GRADE for HTA

The workshop is 3-hours and is led by Tara Cowling, Founder and President of Medlior, and Dr Ahmed Abou-Setta, Director of Knowledge Synthesis, George and Fay Yee Centre for Healthcare Innovation (University of Manitoba) and Manitoba SPOR SUPPORT Unit. The workshop will be hosted by Medlior on the Zoom platform. Organizational attendance is limited to 100 attendees. The cost for the workshop is $6400 CAD. After the meeting, a PDF copy of the presentation slide deck along with Q&A meeting notes will be provided.

For more information, please contact us at

How Can We Help

Our team is comprised of carefully selected professionals who work in their field of expertise guaranteeing that no matter which service you require, you will be working with an expert. Through comprehensive processes, access to specialized research tools, and precise methodology, our experienced specialists bring value to every project. From consultation to completion, whatever your research questions are, they will be answered and explained clearly and concisely.

Contact Us now to discuss your project.